OPT Opthea

Opthea to Participate in the 23ʳᵈ Annual Needham Virtual Healthcare Conference 

Opthea to Participate in the 23ʳᵈ Annual Needham Virtual Healthcare Conference 

MELBOURNE, Australia and PRINCETON, N.J., April 04, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that management will present at the 23rd Annual Needham Virtual Healthcare Conference and participate in one-on-one investor meetings on April 11, 2024.

23rd Annual Needham Virtual Healthcare Conference Presentation Details:

Date:Thursday, April 11th
Time:3:45 p.m. ET
Presenter:Frederic Guerard, Pharm D, CEO
Webcast Link
  

A webcast of the Needham presentation can be accessed under “Events & Presentations” in the Investor Relations section of the Company’s website, .

About Opthea

Opthea (ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to address the unmet need in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).

Opthea’s lead product candidate, sozinibercept, is being evaluated in two pivotal Phase 3 clinical trials (COAST, NCT04757636, and ShORe, NCT04757610,) for use in combination with standard-of-care anti-VEGF-A monotherapies to improve overall efficacy and deliver superior vision gains compared to the standard-of-care anti-VEGF-A agents. To learn more, visit our website and follow us on X and LinkedIn.

Authorized for release to ASX by Fred Guerard, CEO

Investor Enquiries

PJ Kelleher

LifeSci Advisors, LLC

Email:

Phone: 617-430-7579

Media:

Silvana Guerci-Lena

NorthStream Global Partners

Join our email database to receive program updates:

Tel: +61 (0) 3 9826 0399, Email: , Web:



EN
04/04/2024

Underlying

OPTOpthea

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Opthea

 PRESS RELEASE
Free
OPT OPTHEA

Opthea Announces Decision to Discontinue Wet AMD Trials

Opthea Announces Decision to Discontinue Wet AMD Trials ShORe Phase 3 topline results accelerated; trial did not meet primary endpoint of mean change in BCVA from baseline to week 52 Opthea and DFA Investors agreed to terminate both COAST and ShORe trials Opthea continues to consider impact of negative trial results under its Development Funding Agreement (DFA) and on the Company as a going concern MELBOURNE, Australia and PRINCETON, N.J., March 31, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing...

March 31, 2025 1 EN
 PRESS RELEASE
Free
OPT OPTHEA

Opthea Announces COAST Phase 3 Trial Topline Results

Opthea Announces COAST Phase 3 Trial Topline Results COAST Phase 3 trial failed to meet primary endpoint of mean change in BCVA from baseline to week 52 Opthea considering impact of negative trial results under its Development Funding Agreement and on the Company as a going concern MELBOURNE, Australia and PRINCETON, N.J., March 24, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular de...

March 24, 2025 1 EN
 PRESS RELEASE
Free
OPT OPTHEA

Opthea Announces Phase 2b Wet AMD Publication

Opthea Announces Phase 2b Wet AMD Publication Baseline angiographic lesion characteristics predictive of clinical response Published in peer-reviewed journal Ophthalmic Surgery, Lasers and Imaging Retina MELBOURNE, Australia and PRINCETON, N.J., March 03, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced the publication of sozinibercept Phase 2b...

March 3, 2025 1 EN
 PRESS RELEASE
Free
OPT OPTHEA

Opthea Reports Half Year Results and Business Updates

Opthea Reports Half Year Results and Business Updates Cash and cash equivalents of $131.9M as of December 31, 2024 Cash runway extends through anticipated topline data readouts of COAST (early 2Q CY25) and ShORe (mid-CY25) MELBOURNE, Australia and PRINCETON, N.J., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced financial results for the six m...

February 28, 2025 1 EN
 PRESS RELEASE
Free
OPT OPTHEA

Opthea Completes Drug Product PPQ Campaign

Opthea Completes Drug Product PPQ Campaign Three consecutive commercial-scale drug product batches successfully produced Supports potential sozinibercept BLA filing in 1H CY2026 MELBOURNE, Australia and PRINCETON, N.J., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced the completion of its drug product Process Performance Qualification (PPQ)...

February 26, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch